Skip to main content
SpringerLink
Log in

Hematologic disorders associated with cancer: III. Coagulation disorders associated with neoplastic disease

  • Chapter
Issues in Supportive Care of Cancer Patients

Part of the book series: Cancer Treatment and Research ((CTAR,volume 30))

  • 99 Accesses

Abstract

Hemorrhagic, thrombotic and embolic complications occur frequently in cancer patients. Diverse hemostatic alterations including impaired plasma coagulation, platelet abnormalities and vascular disorders account for these defects. Not only have these defects been ascribed to an effect of the malignancy, but in fact the entire sequence of cancer cell growth and metastasis is intimately entwined with the hemostatic system.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Billroth T. 1878. Lectures on surgical pathology and therapeutics (translated from the 8th edition). The New Sydenham Society.

    Google Scholar 

  2. Chew E, Wallace AC. 1976. Demonstration of fibrin in early stages of experimantal metastasis. Cancer Res 36:1904–1909.

    CAS  PubMed  Google Scholar 

  3. Peterson HI. 1977. Fibrinolysis and antifibrinolytic drugs in the growth and spread of tumors. Cancer Treat Rep 1:213–217.

    Article  Google Scholar 

  4. Ross R, Voge A. 1978. The platelet derived growth factor: Review. Cell 14:203–210.

    Article  CAS  PubMed  Google Scholar 

  5. Cliffton EE, Agostino VMD. 1964. Effect of inhibitors of fibrinolytic enzymes on development of pulmonary metastasis. J Natl Cancer Inst 33:753–763.

    CAS  PubMed  Google Scholar 

  6. Zacharski LR, Henderson WG, Rickles FR et al. 1981. Effect of warfarin on survival in small cell carcinoma of the lung. JAMA 245:831–835.

    Article  CAS  PubMed  Google Scholar 

  7. Rickles FR, Edwards RL. 1983. Activation of blood coagulation in cancer: Trousseau’s syndrome revisited. Blood 62:14–31.

    CAS  PubMed  Google Scholar 

  8. Trousseau A. 1865. Phlegmasia alba dolens. Clinique Medicale de l’Hotel-dieu de Paris, London. New Sydenham Society 3:94.

    Google Scholar 

  9. Sack GH, Levin J, Bell W. 1977. Trousseau’s syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms. Clinical, pathologic and therapeutic features. Medicine 56:1–37.

    Article  PubMed  Google Scholar 

  10. Bick RL. 1978. Alterations of hemostasis with malignancy. Sem Thromb. Hemost 5:1–26.

    CAS  Google Scholar 

  11. Ambrus JL, Ambrus CM, Mink IB et al. 1975. Causes of death in cancer patients. J Med 6:61–64.

    CAS  PubMed  Google Scholar 

  12. Ambrus JL, Ambrus CM, Pickern J et al. 1975. Hematologic changes and thromboembolic complications in neoplastic disease and their relationship to metastasis. J Med 6:433–458.

    CAS  PubMed  Google Scholar 

  13. Weiss RB, Toriney DC, Holland JF et al. 1981. Venous thrombosis during multimodal treatment of primary breast carcinoma. Cancer Treat Rep 65:677–679.

    CAS  PubMed  Google Scholar 

  14. Kasimis BS, Spiers AS. 1979. Thrombotic complications in patients with advanced prostatic cancer treated with chemotherapy. Lancet 1:159.

    Article  CAS  PubMed  Google Scholar 

  15. Pineo GF, Brain MC, Galkes AS et al. 1974. Tumors, mucus production and hypercoagulability. Ann NY Acad Sci 230:262–270.

    Article  CAS  PubMed  Google Scholar 

  16. Schafer AI. 1985. The hypercoagulable states. Ann. Intern Med 102:814–828.

    Article  CAS  PubMed  Google Scholar 

  17. Gore JM, Appelbaum JS, Greene HL et al. 1982. Occult cancer in patients with acute pulmonary embolism. Ann Intern Med 96:556–560.

    Article  CAS  PubMed  Google Scholar 

  18. Rohner RF, Prior JT, Sipple JH. 1966. Mucinous malignancies, venous thrombosis and terminal endocarditis with emboli. Cancer 19:1805–1812.

    CAS  Google Scholar 

  19. Sun NC, McAfee WM, Gibert JM et al. 1979. Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Am J Clin Path 71:10–16.

    CAS  PubMed  Google Scholar 

  20. Peusher FW, Cleton FJ, Armstrong L et al. 1980. Significance of plasma fibrinopeptide A (fpA) in patients with malignancy. J Lab Clin Med 96:5–14.

    Google Scholar 

  21. Rickles FR, Edwards RL, Baub C et al. 1983. Abnormalities of blood coagulation in patients with cancer. Cancer 51:301–307.

    Article  CAS  PubMed  Google Scholar 

  22. Pineo GF, Regorezi F, Hatton MWC. 1973. The activation of coagulation by extracts of mucin: a possible pathway of intravascular coagulation accompanying adenocarcinomas. J Lab Clin Med 82:255–260.

    CAS  PubMed  Google Scholar 

  23. Gralnick HR, Sultan C. 1975. Acute promyelocytic leukemia: Haemorrhagic manifestation and morphologic criteria. Br J Haematol 29:373–376.

    Article  CAS  PubMed  Google Scholar 

  24. Drapkin RI, Gee TS, Dowling MD et al. 1978. Prophylactic heparin therapy in acute promyelocytic leukemia. Cancer 41:2484–2490.

    Article  CAS  PubMed  Google Scholar 

  25. Goldsmith GH Jr. 1984. Hemostatic disorders associated with neoplasia. In: Disorders of Hemostasis. Ratnoff OD, Forbes CD, (eds). Grune & Stratton, Orlando, pp 351–363.

    Google Scholar 

  26. Cliffon EC, Grossi CE. 1955. Fibrinolytic activity of human tumors as measured by the fibrinplate method. Cancer 8:1146–1147.

    Article  Google Scholar 

  27. Davidson JF, McNicol GP, Frank GC. 1969. Plasminogen-activator producing tumor. Br. Med J 1:88–91.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Rachmilewitz EA. 1967. Defibrination syndrome followed by hypercoagulable state. Thromb Daith Haemorh 17:120–128.

    CAS  Google Scholar 

  29. Soong BC, Miller sp. 1970. Coagulation disorders in cancer III. Fibrinolysis and inhibitors. Cancer 25:867–874.

    Article  CAS  PubMed  Google Scholar 

  30. Felten A, Straub RW, Frick PD. 1969. Dysfibrinogemia in a patient with primary hepatoma. First observation of an acquired abnormality in fibrin momomer aggregation. N. Engl J Med 280:405–409.

    Article  Google Scholar 

  31. Green G, Thomson JM, Dymock IW et al. 1976. Abnormal fibrin polymerization in liver disease. Br J Haematol 34:427–439.

    Article  CAS  PubMed  Google Scholar 

  32. McGrath K, Koutts J. 1975. A case of Hageman factor deficiency with myeloid leukemia. Aust NE J Med 5:155–157.

    Article  CAS  Google Scholar 

  33. Rasche Dietrich M, Gaus W et al. 1974. Factor XIII-activity and fibin subunit structure in acute leukemia. Biomed 21:61–66.

    Google Scholar 

  34. Haseqawa DIC, Bennett AJ, Coccia PF et al. 1980. Factor V deficiency in Philadelphia-positive chronic myelogenous leukemia. Blood 56:585–595.

    Google Scholar 

  35. Phillips JP, O’Shea MJ. 1977. A new coagulation defect associated with a case of melanomatosis. J Clin Path 30:547–550.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  36. Brody JI, Haidar MD, Rossman RE. 1979. A hemorrhagic syndrome in Waldenstrom’s macroglobinemia secondary to immunoadsorption of factor VIII. N Engl J Med 300:408–410.

    Article  CAS  PubMed  Google Scholar 

  37. Wautier JL, Levy-Toledano S, Caen JP. 1976. Acquired von Willebrand’s syndrome and thrombopathy in a patient with chronic lymphocytic leukemia. Scand j Haematol 16:128–134.

    Article  CAS  PubMed  Google Scholar 

  38. Joist JH, Cowein JF, Zimmerman TS. 1978. Acquired von Willebrand’s disease. N Engl J Med 298:988–991.

    Article  CAS  PubMed  Google Scholar 

  39. Noronha PA, Hruby MA, Maurer HS. 1979. Acquired von Willebrand disease in a patient with Wilm’s tumor. J Peds 95:997–999.

    Article  CAS  Google Scholar 

  40. Shapiro SS, Hultin M. 1975. Acquired inhibitors to the blood coagulation factors. Sem Thromb Hemostat 1:336–351.

    Google Scholar 

  41. Furie B, Voo L, Kieth PW. 1981. Mechanism of factor X deficiency in sytemic amyloidosis. N Engl J Med 304:827–830.

    Article  CAS  PubMed  Google Scholar 

  42. Greipp PR, Kyle RA, Bowie EW. 1979. Factor X deficiency in primary amyloidosis: resolution after splenectomy. N Engl J Med 301:1050–1051.

    Article  CAS  PubMed  Google Scholar 

  43. Lackner H. 1973. Hemostatic abnormalities associated with dysproteinemias. Sem Hematol 10:125–133.

    CAS  Google Scholar 

  44. Palmer RN, Rick ME, Rick PD. 1984. Circulating heparin sulfate anticoagulant in a patient with a fatal bleeding disorder. N Engl J Med 310:1696–1699.

    Article  CAS  PubMed  Google Scholar 

  45. Khoory MS, Nesheim ME, Bowie W. 1980. Circulating heparin sulfate proteoglycan anticoagulant from a patient with a plasma cell disorder. J Clin Invest 65:666–673.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  46. Perkins HA, McKenzie MR, Fudenberg HH. 1970. Hemostatic defects in dysproteinemias. Blood 35:695–707.

    CAS  PubMed  Google Scholar 

  47. Goldsmith GH, Saito H, Muir WA. 1981. Labile anticoagulant in a patient with lymphoma. Am J Hematol 10:305–311.

    Article  CAS  PubMed  Google Scholar 

  48. Scleider MA, Nachman RL, Jaffe EA et al. 1976. A clinical study of the lupus anticoagulant. Blood 48:499–509.

    Google Scholar 

  49. Yanq HC, Kuzur M. 1977. Procoagulant specificity of factor VIII inhibitor. Br J Haematol 37:429–433.

    Article  Google Scholar 

  50. Mueh JR, Herbst KD, Rapaport SI. 1980. Thrombosis in patients with lupus anticoagulants. Ann Intern Med 92:156–159.

    Article  CAS  PubMed  Google Scholar 

  51. Criel A, Collen D, Masson PL. 1978. A case of IgM antibodies which inhibit the contact activation of blood coagulation. Thromb Res 12:883–892.

    Article  CAS  PubMed  Google Scholar 

  52. Campbell EB, Sanal S, Mattson J et al. 1980. Factor VII inhibitor. Am J Med 68:962–964.

    Article  CAS  PubMed  Google Scholar 

  53. Slickter SJ, Harker LA. 1974. Hemostasis in malignancy. Ann NY Acad Sci 230:252–261.

    Article  Google Scholar 

  54. Ingle JN, Tormey DC, Tan HK. 1978. The bone marrow examination in breast cancer. Cancer 41:67–674.

    Article  Google Scholar 

  55. Kim HD, Boggs DR. 1979. A syndrome resembling idiopathic thrombocytopenia purpura in 10 patients with diverse forms of cancer. Am J Med 67:371–276.

    Article  CAS  PubMed  Google Scholar 

  56. Bellone JD, Kunnicki TH, Asrer RH. 1983. Immune thrombocytopenia associated with carcinoma. Ann Intern Med 99:470–472.

    Article  CAS  PubMed  Google Scholar 

  57. Brook J, Konwaler BE. 1965. Thrombotic thrombcytopenic purpura. Association with metastatic gastric carcinoma and a possible autoimmune disorder. Calif Med 102:222–227.

    CAS  PubMed Central  PubMed  Google Scholar 

  58. Friedman IA, Schwartzso, Leifhold SL. 1964. platelet function defects with bleeding. Arch Intern Med 113:177–185.

    Article  Google Scholar 

  59. Perkins HA, Mackenzie MR, Fudenberg HH. 1970. Hemostatic defects in dysproteinemias. Blood 35:695–707.

    CAS  PubMed  Google Scholar 

  60. Pachter MR, Johnson SA, Neblett TR et al. 1959. Bleeding, platelets and macroglobulinemia. Am J Clin Pathol 31:467–482.

    CAS  PubMed  Google Scholar 

  61. Saraya AK, Kasturi J, Kishan R. 1972. A study in hemostasis in macroglobulinemia. Acta Haematol 47:33–42.

    Article  Google Scholar 

  62. Penny R, Castaldi Pa, Whitsed HM. 1971. Inflammation and haemostasis in paraproteinemias. Br J Haematol 20:35–44.

    Article  CAS  PubMed  Google Scholar 

  63. Lacker H. 1973. Hemostatic abnormalities associated with dysproteinemias. Sem. Hematol 10:125–133.

    Google Scholar 

  64. Brown CH, Bradshaw MW, Natelson EA et al. 1976. Defective platelet function following the administration of penicillin compounds. Blood 47:949–956.

    CAS  PubMed  Google Scholar 

  65. Burgdorf W, Mukal K, Rosai J. 1979. Immunohistochemical identification of factor VIII in endothelial cells of normal skin and in cutaneous lesions of alleged vascular nature. Clin Res 27: 523A.

    Google Scholar 

  66. Lewis B, Abrams D, Ziegler J et al. 1983. Single agent or combination chemotherapy of Kaposi’s sarcoma in acquired immune deficiency sydrome. (Abstract) Pro Am Soc Clin Oncol 2:59.

    CAS  Google Scholar 

  67. Laubenstein LJ, Krigel RL, Hymes KB et al. 1983. Treatment of epidemic Kaposi’s sarcoma with vp-16–213 and a combination of doxorubicin, bleomycin and vinblastine. (Abstract) Pro Am Soc Clin Oncol 2:228.

    Google Scholar 

  68. Groopman JE, Gottlieb MS, Goodman J et al. 1984. Recombinant alpha-2 interferon therapy for Kaposi’s sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med 100:671–676.

    Article  CAS  PubMed  Google Scholar 

  69. Peters W. 1985. Personal communication.

    Google Scholar 

  70. Mintzer DM, Real FX, Jouino L. 1985. Treatment of kaposi’s sarcoma and thrombocytopenia with vincristine in patients with the acquired immunodeficiency syndrome. Ann Intern Med 102:200–202.

    Article  CAS  PubMed  Google Scholar 

  71. Kitchens CS. 1984. The purpuric disorders. Sem Thromb Hemostat 10:173–189.

    Article  CAS  Google Scholar 

  72. Kyle RA, Bayrd ED. 1975. Amyloidosis. Review of 236 cases. Medicine (Baltimore) 54:271–299.

    Article  CAS  Google Scholar 

  73. Zlotnick A, Shahin W, Rachmilewltz EA. 1969. Studies in cryofibrinogenemia. Acta Haematol 42:8–17.

    Article  CAS  PubMed  Google Scholar 

  74. Prockop DJ, Kiuirikko KI. 1967. Hydroxyproline and the metabolism of collagen. In: Biology of collagen vol 2 of treatise on collagenld. Gould S (ed).Academic Press, London, p 230.

    Google Scholar 

  75. Ramsay NIC, Coccia PF, Kriuit W et al. 1977. The effect of L-asparaginase on plasma coagulation factors in acute lymphoblastic leukemia. Cancer 40:1398–1401.

    Article  CAS  PubMed  Google Scholar 

  76. Monto RW, Talley RW, Caldwell MJ. 1969. Observations on the mechanisms of hemorrhagic toxicity in mithramycin therapy. Cancer Res 29:697–703.

    CAS  PubMed  Google Scholar 

  77. Ahr DJ, Scialla SJ, Kimball DB. 1978. Acquired platelet dysfunction following mithramycin therapy. Cancer 41:448–454.

    Article  CAS  PubMed  Google Scholar 

  78. Bick RL, Fekete WF, Wilson WL. 1976. Adriamycin and fibrinolysis. Thromb. Res 8:467–475.

    Article  CAS  PubMed  Google Scholar 

  79. Bick RL, Feket L, Murano G. 1976. Daunamycin and fibrinolysis. Thromb Res 9:201–203.

    Article  CAS  PubMed  Google Scholar 

  80. Klener P, Kubisz P, Suranova J. 1977. Influence of cytotoxic drugs on platelet functions and coagulation. Thromb Haemostat 37:53–61.

    CAS  Google Scholar 

Download references

Authors
  1. Richard H. Steingart
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Baystate Medical Center, Springfield, MA, 01199, USA

    Donald J. Higby M.D. (Chief Hematology/Oncology Service) (Chief Hematology/Oncology Service)

Rights and permissions

Reprints and permissions

Copyright information

© 1986 Martinus Nijhoff Publishers, Boston

About this chapter

Cite this chapter

Steingart, R.H. (1986). Hematologic disorders associated with cancer: III. Coagulation disorders associated with neoplastic disease. In: Higby, D.J. (eds) Issues in Supportive Care of Cancer Patients. Cancer Treatment and Research, vol 30. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2325-9_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-2325-9_3

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-9429-0

  • Online ISBN: 978-1-4613-2325-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation